Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.78), $0.03 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.36 million versus the consensus estimate of $4.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.